CEO: Mihael Hristos Polymeropoulos

Sector: Health Technology
Industry:Biotechnology

Exchange: NASDAQ

Country: US

Description: Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.


Key numbers

Market Capitalization:554233080
Shares Outstanding: 54550500
Float: 52497274
Next Earning Date:2020-08-05
TTm EPS: 2.1893
TTm Dividend Rate:
200 days moving average:12.79
50 days moving average: 11.31
One day percent Change: 4.86



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,